Journal
ANNALS OF MEDICINE
Volume 43, Issue 5, Pages 366-374Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/07853890.2011.554429
Keywords
Dexlansoprazole; dual delayed release formulation; gastroesophageal reflux disease; heartburn; proton pump inhibitor
Categories
Funding
- AstraZeneca
- Wyeth
- Takeda
Ask authors/readers for more resources
Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a novel system, the dual delayed release formulation. The drug has been shown to be efficacious in healing erosive esophagitis as compared with lansoprazole. When compared to placebo, dexlansoprazole provided significantly higher maintenance rates for healed esophageal mucosa in patients with erosive esophagitis and symptom control in patients with non-erosive reflux disease. Dexlansoprazole could be taken without regard to food. Overall, dexlansoprazole is well tolerated and has a comparable side-effect profile to lansoprazole.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available